Theralase Technologies (CVE:TLT) Shares Climb 13.2% – Should You Buy?

by · The Markets Daily

Shares of Theralase Technologies Inc. (CVE:TLT – Get Free Report) traded up 13.2% on Thursday. The company traded as high as C$0.22 and last traded at C$0.21. Approximately 284,162 shares were traded during trading, an increase of 20% from the average daily volume of 236,993 shares. The stock had previously closed at C$0.19.

Theralase Technologies Stock Up 15.8%

The firm’s 50 day simple moving average is C$0.18 and its 200-day simple moving average is C$0.23. The company has a debt-to-equity ratio of 2.17, a current ratio of 5.48 and a quick ratio of 3.40. The company has a market cap of C$68.31 million, a price-to-earnings ratio of -15.71 and a beta of -1.01.

Theralase Technologies Company Profile

(Get Free Report)

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.

Featured Stories